FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 677 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Over 600 people in England set to benefit from innovative lung... December 1, 2021 Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to... March 14, 2025 Higher Pregnancy Rates and No Impact on Prognosis with Embryo/Oocyte Cryopreservation... June 26, 2024 Load more HOT NEWS Medicare Open Enrollment is Here! Young Mom Gives Birth To Healthy Baby Boy In The Midst... Mediterranean Diet Associated with a Higher Probability of Response in Patients... seven Interesting Facts about Malignant tumors Boy Between the sheets
